구독하기
연구 모델
모델 라이브러리
연구용 마우스 모델
맞춤형 모델 제작
전임상 연구지원
완전 인간 항체 라이브러리
huRHO-P347S Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
huRHO-P347S Mouse
제품명
huRHO-P347S Mouse
제품 ID
C002130
품종 계통
C57BL/6Cya-Rhotm5(hRHO*P347S)/Cya
Backgroud
C57BL/6Cya
상태
이 마우스 계통을 논문에서 사용할 경우, “huRHO-P347S Mouse (카탈로그 번호 C002130)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
기본 정보
관련 자료
기본 정보
유전자명
유전자 별칭
RP4, OPN2, CSNBAD1
NCBI ID
염색체
Chr 3
MGI ID
더보기
Datasheet
품종 계통 설명
Retinitis pigmentosa (RP) is a hereditary retinal disease with a global prevalence of approximately 1:5000-1:3000. RP is highly clinically and genetically heterogeneous, with mutations in the rhodopsin (RHO) gene causing approximately 25% of dominant RP [1]. The rhodopsin encoded by the RHO gene is closely associated with visual light transduction and GPCR downstream signals. Rhodopsin is essential for the transmission of light signals in the process of vision formation. Most RHO mutations lead to high levels of rhodopsin expression in photoreceptor cells, causing many mutant proteins to be abnormally located and aggregated in cells. This results in the apoptosis of photoreceptor cells, which cannot perform normal light signal transduction functions. Additionally, mutations in the RHO gene are associated with congenital stationary night blindness (CSNB) [2-6]. The P347S (Pro347Ser) mutation is located in the C-terminal cytoplasmic tail of the rhodopsin (RHO) protein. It may impair the polarized transport and localization of rhodopsin to rod photoreceptor outer segments, resulting in abnormal distribution of some mutant proteins and the accumulation of extracellular vesicles, ultimately leading to progressive photoreceptor degeneration. P347S is a reported pathogenic mutation associated with autosomal dominant retinitis pigmentosa (adRP) [7-9].
The huRHO-P347S mouse was generated using gene-editing technology by replacing the sequence from the start codon to the region downstream of exon 5 of the mouse Rho gene with the corresponding human RHO gene sequence and introducing the p.P347S (CCG to TCG) point mutation into exon 5 of the human RHO gene. This model can be used to investigate the pathogenesis and progression of RHO mutation-associated autosomal dominant retinitis pigmentosa (adRP) and to evaluate potential therapeutic strategies in preclinical studies. Based on the self-developed technological innovation of TurboKnockout fusion BAC recombination, Cyagen can also provide customized services for different point mutations to meet the needs of a wide range of R&D personnel regarding the pharmacodynamics of retinitis pigmentosa (RP) and other preclinical needs.
Reference
Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006 Nov 18;368(9549):1795-809.
Meng D, Ragi SD, Tsang SH. Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa. Mol Ther. 2020 Oct 7;28(10):2139-2149.
Sakami S, Maeda T, Bereta G, Okano K, Golczak M, Sumaroka A, Roman AJ, Cideciyan AV, Jacobson SG, Palczewski K. Probing mechanisms of photoreceptor degeneration in a new mouse model of the common form of autosomal dominant retinitis pigmentosa due to P23H opsin mutations. J Biol Chem. 2011 Mar 25;286(12):10551-67.
Dryja T P, Mcgee T L, Reichel E, et al. A point mutation of the rhodopsin gene in one form of retinitispigmentosa[J]. Nature, 1990, 343(6256):364-366.
Zhang X, Fu W, Pang C P, et al. Screening for point mutations in rhodopsin gene among one hundred Chinese patients with retinitis pigmentosa[J]. Chinese Journal of Medical Genetics, 2002, 19(6):463-466.
Gamundi M J, Hernan I, Muntanyola M, et al. Transcriptional expression of cis-acting and trans-acting splicing mutations cause autosomal dominant retinitis pigmentosa[J]. Human Mutation, 2008.
Li T, Snyder WK, Olsson JE, Dryja TP. Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments. Proceedings of the National Academy of Sciences. 1996;93(24):14176–14181.
Athanasiou D, Aguila M, Bellingham J, Li W, McCulley C, Reeves PJ, Cheetham ME. The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. Prog Retin Eye Res. 2018 Jan;62:1-23.
Bonilha VL, Rayborn ME, Bell BA, Marino MJ, Beight CD, Pauer GJ, Traboulsi EI, Hollyfield JG, Hagstrom SA. Retinal histopathology in eyes from patients with autosomal dominant retinitis pigmentosa caused by rhodopsin mutations. Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2161-9.
변형 전략
The sequence from the start codon to the region downstream of exon 5 of the mouse Rho gene was replaced with the corresponding human RHO gene sequence, and the p.P347S (CCG to TCG) point mutation was introduced into exon 5 of the human RHO gene.

Figure 1. Diagram of the gene editing strategy for the generation of huRHO-P347S mice.
응용 분야
Research on retinitis pigmentosa (RP);
Research on other retinal diseases.
관련 자료
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
